This morning, the Information Office of the State Council held a series of press conferences on the theme of “Starting the 15th Five-Year Plan” series to introduce the situation relating to promoting high-quality development of health insurance and better serving the Chinese modernization drive. According to reports, since 2018, the dynamic adjustment mechanism for the medical insurance drug catalogue has continued to be improved, and a total of 949 new drugs have been added, of which 199 are innovative drugs, so that more patients can use and use good medicines for first aid and life saving. Facing the new situation of rapid development of the pharmaceutical industry during the “15th Five-Year Plan” period, the health insurance department will continue to adjust the basic medical insurance drug catalogue every year to include more eligible innovative drugs in major diseases and key areas such as tumors, chronic diseases, rare diseases, and childhood diseases in medical insurance reimbursement. At the same time, optimize and improve the commercial health insurance innovative drug catalogue, and recommend advance payment of commercial medical insurance etc. for innovative drugs that exceed the scope of basic medical insurance, have a high degree of innovation, great clinical value, and significant patient benefits.

Zhitongcaijing · 2d ago
This morning, the Information Office of the State Council held a series of press conferences on the theme of “Starting the 15th Five-Year Plan” series to introduce the situation relating to promoting high-quality development of health insurance and better serving the Chinese modernization drive. According to reports, since 2018, the dynamic adjustment mechanism for the medical insurance drug catalogue has been continuously improved, and a total of 949 new drugs have been added, of which 199 are innovative drugs, so that more patients can use and use good medicines for first aid and life saving. Facing the new situation of rapid development of the pharmaceutical industry during the “15th Five-Year Plan” period, the health insurance department will continue to adjust the basic medical insurance drug catalogue every year to include more eligible innovative drugs in major diseases and key areas such as tumors, chronic diseases, rare diseases, and childhood diseases in medical insurance reimbursement. At the same time, optimize and improve the commercial health insurance innovative drug catalogue, and recommend advance payment of commercial medical insurance etc. for innovative drugs that exceed the scope of basic medical insurance, have a high degree of innovation, great clinical value, and significant patient benefits.